An antisense drug designed to decrease the amount of mutant and normal TTR made by the liver, aimed at reducing TTR deposits and slowing or stopping the progression of hereditary ATTR amyloidosis (hATTR).

A potential treatment for familial chylomicronemia syndrome (FCS) designed to reduce the production of a protein in the liver that regulates plasma triglycerides.